The ASCO Post

The ASCO Post
Initial Therapy for Asymptomatic Follicular Lymphoma: Start With Watch and Wait or Rituximab

For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic.

The ASCO Post
Study Finds Survival Disparities and Mutational Differences for Black Patients Younger Than 60 With AML

There is an urgent need to address this survival disparity in younger Black patients, as well as to conduct larger studies to establish molecular risk profiles of these patients, according...

The ASCO Post
ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL

Many patients with diffuse large B-cell lymphoma may be cured by autologous stem cell transplant, but as many as half eventually relapse.

The ASCO Post
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma

The phase II ZUMA-12 trial found axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma.

The ASCO Post
Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL

This study showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival for patients who...

The ASCO Post
Early Signs of Risk for Myeloproliferative Neoplasms May Appear in Childhood or in Utero

Genetic mutations linked to myeloproliferative neoplasms may emerge in childhood or even in utero, decades before they cause cancer, according to a late-breaking abstract presented...

The ASCO Post
Multiple Myeloma Patient Similarity Network Identifies Prognostic Subgroups With Distinct Genetic and Clinical Features

An analysis by Bhalla et al of multiomics data from newly diagnosed patients with MM has identified 3 main patient groups and 12 prognostic subgroups based on five data types generated from...

The ASCO Post
ZUMA-5 Trial Finds Axicabtagene Ciloleucel Shows Activity in Patients With Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma treated with the cellular immunotherapy. 

The ASCO Post
Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia

A phase I/II study found that IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed or refractory BPDCN. 

The ASCO Post
ASH 2020: Early Research Shows CD58 May Be a Biomarker for Response to Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma

In a study presented at the 2020 ASH Annual Meeting & Exposition investigators reported CD58 status may be an important biomarker of durable response to CAR T-cell therapy in these patients

The ASCO Post
Subscribe to The ASCO Post

source list reference